ORIFARM GENERICS HOLDING A/S: Financial statements 2014
CVR: 27347223
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
ORIFARM GENERICS HOLDING A/S (CVR 27347223) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 8,233,000 and a net result of DKK 4,116,000 compared with DKK -150,000 the year before. That is an increase of 21.2% compared with the year before. Equity in the 2014 report amounted to DKK 15,341,000. The solvency ratio was 34.1%.
- Gross Profit
- DKK 8,233,000
- Profit/Loss
- DKK 4,116,000
- Equity
- DKK 15,341,000
- Total Assets
- DKK 45,015,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 8.2M | 4.1M | 15.3M | - |
| 2013 | - | 6.8M | -150K | 11.5M | - |
| 2012 | - | 13.1M | 7.1M | 12M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
ORIFARM GENERICS HOLDING A/S has published its annual report for 2013. Gross profit came to DKK 6,792,000, and the net result was DKK -150,000.
As of May 20, 2014, Jean-Francois Loumeau has left the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 13, 2014, Claudio Albrecht has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of May 13, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM GENERICS HOLDING A/S.
About ORIFARM GENERICS HOLDING A/S
ORIFARM GENERICS HOLDING A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2003. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named COPYFARM HOLDING A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GROUP A/S. The company has 0 employees (2016). In 2025, the company reported revenue of DKK 459,463,000 and a net result of DKK 273,125,000 compared with DKK 89,363,000 the year before. Equity in the 2025 report amounted to DKK 2,399,752,000.
